Periodic Reporting for period 1 - NR2F6-AIM (NR2F6 Blockade as Adoptive Immune Cell Therapy for Metastatic Melanoma)
Período documentado: 2024-09-01 hasta 2026-02-28
Mission statement: Enhancing immunotherapy for cancer
Metastatic melanoma (MM) is one of the most lethal skin cancers, with rising incidence, high relapse rates and substantial clinical and economic burden despite advances in targeted and immune checkpoint‑based therapies. Current synthetic immunotherapies, including ACT (TIL‑ and CAR‑T‑based), still show limited response rates, long and complex manufacturing, high costs and relevant side effects, so there remains a clear need for safer and more accessible treatments that can overcome tumor‑induced immune suppression.
NR2F6‑AIM addresses this need by exploring a novel ACT concept in which the intracellular immune checkpoint NR2F6 is genetically inhibited in T cells to improve their fitness, trigger a strong secondary and antigen‑agnostic host anti‑tumor immune response, and enhance responsiveness to immunotherapies. The four main objectives in preclinical mouse subcutaneous tumor model systems were: (1) to generate in vivo evidence that NR2F6‑modified ACT can safely influence subcutaneous solid tumor control and enhance responses to approved immunotherapies such as CAR‑T; (2) to establish ex vivo feasibility in human PBMC‑derived CAR‑T cells under solid tumor‑relevant conditions; (3) to develop an IP strategy around NR2F6‑based ACT; and (4) to analyze market needs, stakeholder interest and commercial pathways to prepare a realistic business case and “go/no‑go” roadmap for potential future clinical and commercial translation.
NR2F6‑AIM progress in these strictly preclinical and preparatory activities is expected to lay the groundwork for subsequent development of NR2F6‑targeted ACT as an innovative option for solid tumors with NR2F6‑driven immune resistance, with the long‑term goal of shortening treatment times, improving safety and broadening access to advanced solid cancer immunotherapies.
Metastatic melanoma (MM) is one of the most lethal skin cancers, with rising incidence, high relapse rates and substantial clinical and economic burden despite advances in targeted and immune checkpoint‑based therapies. Current synthetic immunotherapies, including ACT (TIL‑ and CAR‑T‑based), still show limited response rates, long and complex manufacturing, high costs and relevant side effects, so there remains a clear need for safer and more accessible treatments that can overcome tumor‑induced immune suppression.
NR2F6‑AIM addresses this need by exploring a novel ACT concept in which the intracellular immune checkpoint NR2F6 is genetically inhibited in T cells to improve their fitness, trigger a strong secondary and antigen‑agnostic host anti‑tumor immune response, and enhance responsiveness to immunotherapies. The four main objectives in preclinical mouse subcutaneous tumor model systems were: (1) to generate in vivo evidence that NR2F6‑modified ACT can safely influence subcutaneous solid tumor control and enhance responses to approved immunotherapies such as CAR‑T; (2) to establish ex vivo feasibility in human PBMC‑derived CAR‑T cells under solid tumor‑relevant conditions; (3) to develop an IP strategy around NR2F6‑based ACT; and (4) to analyze market needs, stakeholder interest and commercial pathways to prepare a realistic business case and “go/no‑go” roadmap for potential future clinical and commercial translation.
NR2F6‑AIM progress in these strictly preclinical and preparatory activities is expected to lay the groundwork for subsequent development of NR2F6‑targeted ACT as an innovative option for solid tumors with NR2F6‑driven immune resistance, with the long‑term goal of shortening treatment times, improving safety and broadening access to advanced solid cancer immunotherapies.
The project carried out four integrated activities covering technological validation, IP consolidation and commercial feasibility.
In Activity 1, a comprehensive series of in vivo experiments in murine solid tumor models compared gene edited NR2F6 knockout with conventional CAR‑T cell designs. NR2F6‑modified ACT inhibited tumor growth, shifted the TIME towards a more inflammatory, immune‑permissive state and improved therapy responses, while safety studies supported a favorable therapeutic index and provided preclinical proof‑of‑concept for further development in non‑clinical models.
In Activity 2, the concept was translated into human systems using ex vivo co‑cultures of human PBMC‑derived CAR‑T cells and tumor cell lines under immunosuppressive‑like conditions. siRNA‑mediated NR2F6 silencing improved effector phenotypes and reduced features of exhaustion, and the team optimized a practical, scalable PBMC‑based protocol defining key parameters for a potential future clinical application, which would still require dedicated clinical development and regulatory evaluation.
Activity 3 strengthened the IP position and defined a forward‑looking IP strategy. Building on our priority patent EP23197471.8 and a successful challenge of competing claims, an updated IP landscape confirmed freedom‑to‑operate and highlighted additional innovation points around the “time‑boxed” platform and its combinations, leading to a staged IP plan and preparation of follow‑up filings to protect NR2F6‑AIM results.
In Activity 4, a specialized consulting firm supported market and competitor analyses, stakeholder engagement and business case development, quantifying the metastatic solid tumor therapeutics market and benchmarking NR2F6‑AIM against ICT, TIL, CAR‑T and TCR‑T approaches. Early interactions with clinicians and biotech partners (including invIOs, Vienna) indicated strong interest in a rapid, non‑viral ACT add‑on to immuno‑oncology regimens and helped outline realistic routes to market such as spin‑off creation, co‑development and out‑licensing.
Overall, the project broadly achieved its planned milestones, including in vivo and ex vivo validation, an optimized PBMC protocol, consolidated IP and market analyses, and a data‑informed “go/no‑go” framework that will guide any future steps towards clinical translation.
In Activity 1, a comprehensive series of in vivo experiments in murine solid tumor models compared gene edited NR2F6 knockout with conventional CAR‑T cell designs. NR2F6‑modified ACT inhibited tumor growth, shifted the TIME towards a more inflammatory, immune‑permissive state and improved therapy responses, while safety studies supported a favorable therapeutic index and provided preclinical proof‑of‑concept for further development in non‑clinical models.
In Activity 2, the concept was translated into human systems using ex vivo co‑cultures of human PBMC‑derived CAR‑T cells and tumor cell lines under immunosuppressive‑like conditions. siRNA‑mediated NR2F6 silencing improved effector phenotypes and reduced features of exhaustion, and the team optimized a practical, scalable PBMC‑based protocol defining key parameters for a potential future clinical application, which would still require dedicated clinical development and regulatory evaluation.
Activity 3 strengthened the IP position and defined a forward‑looking IP strategy. Building on our priority patent EP23197471.8 and a successful challenge of competing claims, an updated IP landscape confirmed freedom‑to‑operate and highlighted additional innovation points around the “time‑boxed” platform and its combinations, leading to a staged IP plan and preparation of follow‑up filings to protect NR2F6‑AIM results.
In Activity 4, a specialized consulting firm supported market and competitor analyses, stakeholder engagement and business case development, quantifying the metastatic solid tumor therapeutics market and benchmarking NR2F6‑AIM against ICT, TIL, CAR‑T and TCR‑T approaches. Early interactions with clinicians and biotech partners (including invIOs, Vienna) indicated strong interest in a rapid, non‑viral ACT add‑on to immuno‑oncology regimens and helped outline realistic routes to market such as spin‑off creation, co‑development and out‑licensing.
Overall, the project broadly achieved its planned milestones, including in vivo and ex vivo validation, an optimized PBMC protocol, consolidated IP and market analyses, and a data‑informed “go/no‑go” framework that will guide any future steps towards clinical translation.
NR2F6‑AIM has advanced ACT for solid tumors beyond the current state of the art in several key dimensions at the preclinical level (see Humer, D., Klepsch, V., Rieder, D. et al. NR2F6 deletion revives CAR‑T cell function and induces antigen‑agnostic immune memory in solid tumors. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69796-0(se abrirá en una nueva ventana)
First, it establishes, for the first time, an intracellular checkpoint inhibition strategy that specifically targets NR2F6 in T cells to reprogram their effector function and to induce a secondary host antitumor response, in which CAR‑mediated cytotoxicity not only kills tumor cells but also promotes endogenous T cell priming in an in situ “kill‑and‑vaccinate” manner. This approach combines the potency of NR2F6 checkpoint blockade with a potentially more favorable safety profile based on a secondary, polyclonal immune response by the patient, thereby reducing the theoretical risk of immune escape driven by antigen loss or clonal restriction.
Second, in principle, the key preclinical results suggest that NR2F6‑modified ACT could be implemented by non‑genomic, siRNA‑based technologies as a point‑of‑care procedure using PBMC‑derived T cells, thereby significantly improving CAR‑T manufacturing compared with conventional TIL and CAR‑T therapies. This non‑viral manufacturing concept might reduce costs, increase patient access and make personalized ACT more compatible with routine clinical workflows in oncology centers, and the optimized protocol together with preclinical data offers an initial blueprint for later translation into a GMP setting and for designing potential first‑in‑human trials in solid tumors such as MM. The central future idea is to use a non‑viral, “time‑boxed” siRNA transfection of PBMC‑derived T cells to transiently silence NR2F6, followed by rapid reinfusion, enabling a one‑day, in‑hospital ACT preparation that avoids lengthy ex vivo expansion and permanent genomic modification while still inducing potent antitumor immunity in a hostile TIME.
Taken together, the project positions NR2F6 as a promising and potentially clinically actionable immune checkpoint and platform target in solid tumors with NR2F6‑driven immune suppression, thereby opening new research and innovation avenues in solid tumor immunotherapy. The consolidated IP portfolio and refined commercial strategy provide a strong basis to develop, own and exploit NR2F6‑based ACT innovations in Europe, with potential benefits for patients, healthcare systems and the biotech sector, and together these achievements deliver a technically validated, IP‑protected and commercially assessed ACT concept that can now be further advanced through dedicated, future clinical development programs.
Figure legend: NR2F6 AIM explored a new way to make personalized immunotherapy more powerful for patients with solid cancers such as melanoma. By switching off the intracellular checkpoint NR2F6 in engineered CAR T cells (upper left), the project showed in preclinical models that these cells not only kill tumors more efficiently but can also “vaccinate” the host immune system to recognize the cancer more broadly by triggering a secondary and polyclonal immune memory beyond the initially targeted CAR antigen (such as MSLN). This work lays the scientific and strategic foundation for future development of faster, safer, more effective and more accessible cell therapies.
First, it establishes, for the first time, an intracellular checkpoint inhibition strategy that specifically targets NR2F6 in T cells to reprogram their effector function and to induce a secondary host antitumor response, in which CAR‑mediated cytotoxicity not only kills tumor cells but also promotes endogenous T cell priming in an in situ “kill‑and‑vaccinate” manner. This approach combines the potency of NR2F6 checkpoint blockade with a potentially more favorable safety profile based on a secondary, polyclonal immune response by the patient, thereby reducing the theoretical risk of immune escape driven by antigen loss or clonal restriction.
Second, in principle, the key preclinical results suggest that NR2F6‑modified ACT could be implemented by non‑genomic, siRNA‑based technologies as a point‑of‑care procedure using PBMC‑derived T cells, thereby significantly improving CAR‑T manufacturing compared with conventional TIL and CAR‑T therapies. This non‑viral manufacturing concept might reduce costs, increase patient access and make personalized ACT more compatible with routine clinical workflows in oncology centers, and the optimized protocol together with preclinical data offers an initial blueprint for later translation into a GMP setting and for designing potential first‑in‑human trials in solid tumors such as MM. The central future idea is to use a non‑viral, “time‑boxed” siRNA transfection of PBMC‑derived T cells to transiently silence NR2F6, followed by rapid reinfusion, enabling a one‑day, in‑hospital ACT preparation that avoids lengthy ex vivo expansion and permanent genomic modification while still inducing potent antitumor immunity in a hostile TIME.
Taken together, the project positions NR2F6 as a promising and potentially clinically actionable immune checkpoint and platform target in solid tumors with NR2F6‑driven immune suppression, thereby opening new research and innovation avenues in solid tumor immunotherapy. The consolidated IP portfolio and refined commercial strategy provide a strong basis to develop, own and exploit NR2F6‑based ACT innovations in Europe, with potential benefits for patients, healthcare systems and the biotech sector, and together these achievements deliver a technically validated, IP‑protected and commercially assessed ACT concept that can now be further advanced through dedicated, future clinical development programs.
Figure legend: NR2F6 AIM explored a new way to make personalized immunotherapy more powerful for patients with solid cancers such as melanoma. By switching off the intracellular checkpoint NR2F6 in engineered CAR T cells (upper left), the project showed in preclinical models that these cells not only kill tumors more efficiently but can also “vaccinate” the host immune system to recognize the cancer more broadly by triggering a secondary and polyclonal immune memory beyond the initially targeted CAR antigen (such as MSLN). This work lays the scientific and strategic foundation for future development of faster, safer, more effective and more accessible cell therapies.